



Appendix A

Claim Amendments

1. - 4. (Canceled)

5. (Currently amended) A lipid-free pharmaceutical
~~medicament composition which is useful for treating or~~
~~preventing a pulmonary infection or inflammation and~~
~~which comprises an effective amount of~~ comprising a
pharmaceutically acceptable active component and
suitable carrier therefore, wherein the active
component comprises ~~is at least substantially the same~~
~~as~~ recombinant surfactant protein A (rSP-A).

6. (Currently amended) A ~~medicament~~ method for preventing
or treating a pulmonary infection in a patient prone
to or afflicted with such condition, comprising
administering to a patient in need thereof a
therapeutically effective amount of a pharmaceutical
composition according to ~~[[of]]~~ claim 5 ~~for treating~~
~~or preventing a pulmonary infection.~~

7. (Currently amended) ~~A medicament composition of~~ The method according to claim 6, wherein the pulmonary infection is bacterial, viral or fungal pneumonia.
8. (Currently amended) ~~A medicament~~ method for preventing or treating a pulmonary inflammation in a patient prone to or afflicted with such condition, comprising administering to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to ~~[[of]]~~ claim 5 ~~for treating or preventing a pulmonary inflammation.~~
9. (Currently amended) ~~A medicament composition of~~ The method according to claim 8, wherein the pulmonary inflammation is bronchopulmonary dysplasia.
10. (Currently amended) ~~A medicament~~ The pharmaceutical composition of claim 5, wherein the rSP-A is ~~at least substantially the same as recombinant SP-A~~ obtained by expression of a genomic sequence coding for SP-A in a suitable expression system.

11. (Currently amended) ~~A medicament~~ The pharmaceutical composition of claim 5, wherein the rSP-A is ~~at least substantially the same as recombinant SP-A~~ obtained by expression of a cDNA coding for SP-A in a suitable expression system.
12. (Currently amended) ~~A medicament~~ The pharmaceutical composition of claim 5, wherein the active component further comprises surfactant protein D (SP-D).
13. (Currently amended) ~~In a~~ A method for preventing or treating a pulmonary infection or inflammation in a ~~subject~~ patient prone to or afflicted with such condition, ~~which method comprises~~ comprising administering to a patient in need thereof ~~[[an]]~~ a therapeutically effective amount of a pharmaceutical composition according to claim 5 ~~pharmaceutically acceptable active component to the subject, the improvement wherein the active component comprises an essential ingredient which is at least substantially the same as recombinant surfactant protein A (rSP-A).~~
14. (Canceled)

15. (Currently amended) A method of preventing or treating
a pulmonary infection or inflammation in a patient
prone to or afflicted with such condition, comprising
administering to a patient in need thereof a
therapeutically effective amount of a pharmaceutical
composition according to claim 12 ~~claim 13~~ ~~wherein the~~
~~active component further comprises surfactant protein~~
~~D (SP-D).~~

16. (Currently amended) An article of manufacture
comprising packaging material and **[[a]]** the
pharmaceutical composition according to claim 5
contained within the packaging material, ~~wherein the~~
~~pharmaceutical composition comprises an active~~
~~ingredient which is at least substantially the same as~~
~~recombinant surfactant protein A,~~ and wherein the
packaging material comprises a label or package insert
which indicates that the active ~~agent~~ component is
useful for preventing or treating a pulmonary
microbial infection or inflammation.

17. (Currently amended) An article of manufacture
comprising packaging material and the pharmaceutical
composition according to claim 12 contained within the
packaging material, wherein the packaging material
comprises a label or package insert which indicates
that the active component is useful for preventing or
treating a pulmonary microbial infection or
inflammation ~~of claim 16 wherein the active agent is~~
~~SP-A.~~